Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases

Related Experiment Video

Updated: Apr 25, 2026

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

11.7K

Ana R Santiago1, Filipa I Baptista2, Paulo F Santos3

  • 1Centre of Ophthalmology and Vision Sciences, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal ; AIBILI, 3000-548 Coimbra, Portugal ; Center for Neuroscience and Cell Biology, Largo Marquês de Pombal, Universidade de Coimbra, 3004-517 Coimbra, Portugal ; Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal.

Mediators of Inflammation
|August 19, 2014
PubMed

Insights

Microglia-driven neuroinflammation is implicated in neurodegenerative diseases. Targeting the adenosine A2A receptor (A2AR) offers a potential therapeutic strategy for brain and retinal conditions.

Area of Science:

  • Neuroscience
  • Immunology
  • Ophthalmology

Background:

  • Microglial cells mediate neuroinflammation, a hallmark of neurodegenerative diseases like Parkinson's and Alzheimer's.
  • The role of neuroinflammation as a cause or consequence in disease progression remains debated, but its chronic presence impacts disease severity.
  • Adenosine, acting via the A2A receptor (A2AR), modulates microglial activity, presenting a potential therapeutic target.

Purpose of the Study:

  • To compare the inflammatory profiles of Parkinson's disease (PD) and Alzheimer's disease (AD) with retinal degenerative diseases such as glaucoma and diabetic retinopathy.
  • To investigate the largely unexplored role of the adenosine A2A receptor (A2AR) in these retinal conditions.
  • To discuss the therapeutic potential of A2AR blockade for both neurodegenerative and retinal degenerative diseases.

Main Methods:

  • Review of existing literature on neuroinflammation in Parkinson's disease, Alzheimer's disease, glaucoma, and diabetic retinopathy.
  • Analysis of the known functions of adenosine and its A2A receptor in microglial cell regulation.
  • Comparative analysis of inflammatory pathways and A2AR involvement across the studied diseases.

Main Results:

  • Chronic neuroinflammation, mediated by microglia, is a common feature in both brain and retinal degenerative diseases.
  • Adenosine A2A receptor (A2AR) activation influences microglial proliferation, migration, and inflammatory responses.
  • A2AR blockade has shown promise in managing various brain diseases, suggesting potential applicability to retinal conditions.

Conclusions:

  • Targeting A2A receptors presents a promising therapeutic avenue for mitigating microglial-mediated neuroinflammation in neurodegenerative and retinal degenerative diseases.
  • Further research is warranted to explore the specific role and therapeutic efficacy of A2AR modulation in glaucoma and diabetic retinopathy.
  • A unified therapeutic strategy targeting A2AR may offer benefits across a spectrum of debilitating neurological and visual impairments.

More Related Videos

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

1.6K
Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions08:47

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Published on: July 26, 2024

3.2K

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
21
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K